288 related articles for article (PubMed ID: 29186568)
21. Identification of a SUFU germline mutation in a family with Gorlin syndrome.
Pastorino L; Ghiorzo P; Nasti S; Battistuzzi L; Cusano R; Marzocchi C; Garrè ML; Clementi M; Scarrà GB
Am J Med Genet A; 2009 Jul; 149A(7):1539-43. PubMed ID: 19533801
[TBL] [Abstract][Full Text] [Related]
22. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM;
Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015
[TBL] [Abstract][Full Text] [Related]
23. Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma.
Bourdeaut F; Miquel C; Richer W; Grill J; Zerah M; Grison C; Pierron G; Amiel J; Krucker C; Radvanyi F; Brugieres L; Delattre O
Pediatr Blood Cancer; 2014 Feb; 61(2):383-6. PubMed ID: 24115570
[TBL] [Abstract][Full Text] [Related]
24. Molecular progression of SHH-activated medulloblastomas.
Korshunov A; Okonechnikov K; Sahm F; Ryzhova M; Stichel D; Sievers P; Meyer J; Schrimpf D; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; von Deimling A; Kool M
Acta Neuropathol; 2019 Aug; 138(2):327-330. PubMed ID: 31030238
[No Abstract] [Full Text] [Related]
25. SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature.
Mangum R; Varga E; Boué DR; Capper D; Benesch M; Leonard J; Osorio DS; Pierson CR; Zumberge N; Sahm F; Schrimpf D; Pfister SM; Finlay JL
Childs Nerv Syst; 2016 Dec; 32(12):2439-2446. PubMed ID: 27444290
[TBL] [Abstract][Full Text] [Related]
26. Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept.
Rieken S; Gaiser T; Mohr A; Welzel T; Witt O; Kulozik AE; Wick W; Debus J; Combs SE
BMC Cancer; 2010 Aug; 10():450. PubMed ID: 20731859
[TBL] [Abstract][Full Text] [Related]
27. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
28. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
Ramaswamy V; Remke M; Bouffet E; Faria CC; Perreault S; Cho YJ; Shih DJ; Luu B; Dubuc AM; Northcott PA; Schüller U; Gururangan S; McLendon R; Bigner D; Fouladi M; Ligon KL; Pomeroy SL; Dunn S; Triscott J; Jabado N; Fontebasso A; Jones DT; Kool M; Karajannis MA; Gardner SL; Zagzag D; Nunes S; Pimentel J; Mora J; Lipp E; Walter AW; Ryzhova M; Zheludkova O; Kumirova E; Alshami J; Croul SE; Rutka JT; Hawkins C; Tabori U; Codispoti KE; Packer RJ; Pfister SM; Korshunov A; Taylor MD
Lancet Oncol; 2013 Nov; 14(12):1200-7. PubMed ID: 24140199
[TBL] [Abstract][Full Text] [Related]
29. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
30. Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature.
Amlashi SF; Riffaud L; Brassier G; Morandi X
Cancer; 2003 Aug; 98(3):618-24. PubMed ID: 12879481
[TBL] [Abstract][Full Text] [Related]
31. Increasing Sufu gene dosage reveals its unorthodox role in promoting polydactyly and medulloblastoma tumorigenesis.
Han B; Wang Y; Yue S; Zhang YH; Kuang L; Gao BB; Wang Y; Zhang Z; Pu X; Wang XF; Hui CC; Yu TT; Liu C; Cheng SY
JCI Insight; 2024 Feb; 9(6):. PubMed ID: 38358805
[TBL] [Abstract][Full Text] [Related]
32. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
[TBL] [Abstract][Full Text] [Related]
33. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors and secondary malignancies in childhood medulloblastoma.
Stavrou T; Bromley CM; Nicholson HS; Byrne J; Packer RJ; Goldstein AM; Reaman GH
J Pediatr Hematol Oncol; 2001 Oct; 23(7):431-6. PubMed ID: 11878577
[TBL] [Abstract][Full Text] [Related]
35. Subgroup and subtype-specific outcomes in adult medulloblastoma.
Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
[TBL] [Abstract][Full Text] [Related]
36. Outcome for children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor (CNS-PNET) - a retrospective analysis spanning 40 years of treatment.
Stensvold E; Krossnes BK; Lundar T; Due-Tønnessen BJ; Frič R; Due-Tønnessen P; Bechensteen AG; Myklebust TÅ; Johannesen TB; Brandal P
Acta Oncol; 2017 May; 56(5):698-705. PubMed ID: 28325133
[TBL] [Abstract][Full Text] [Related]
37. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology.
von Bueren AO; von Hoff K; Pietsch T; Gerber NU; Warmuth-Metz M; Deinlein F; Zwiener I; Faldum A; Fleischhack G; Benesch M; Krauss J; Kuehl J; Kortmann RD; Rutkowski S
Neuro Oncol; 2011 Jun; 13(6):669-79. PubMed ID: 21636711
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker.
Korshunov A; Okonechnikov K; Sahm F; Ryzhova M; Stichel D; Schrimpf D; Ghasemi DR; Pajtler KW; Antonelli M; Donofrio V; Mastronuzzi A; Rossi S; Camassei FD; Buccoliero AM; Haberler C; Slavc I; Dahiya S; Casalini B; Sievers P; Meyer J; Kumirova E; Zheludkova O; Golanov A; Jones DTW; Pfister SM; Kool M; von Deimling A
Acta Neuropathol; 2020 Mar; 139(3):583-596. PubMed ID: 31781912
[TBL] [Abstract][Full Text] [Related]
39. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
40. Tumor suppressor gene co-operativity in compound Patched1 and suppressor of fused heterozygous mutant mice.
Svärd J; Rozell B; Toftgård R; Teglund S
Mol Carcinog; 2009 May; 48(5):408-19. PubMed ID: 18781608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
